Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation.

Abrahams MR, Joseph SB, Garrett N, Tyers L, Moeser M, Archin N, Council OD, Matten D, Zhou S, Doolabh D, Anthony C, Goonetilleke N, Karim SA, Margolis DM, Pond SK, Williamson C, Swanstrom R.

Sci Transl Med. 2019 Oct 9;11(513). pii: eaaw5589. doi: 10.1126/scitranslmed.aaw5589.

PMID:
31597754
2.

Four Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May be Attributed to Rectal Swab Use.

Williams BB, Green SJ, Bosch RJ, Chan ES, Jacobson JM, Margolis DM, Engen P, Landay AL, Wilson CC; A5286 protocol team.

Pathog Immun. 2019 Sep 23;4(2):235-250. doi: 10.20411/pai.v4i2.290. eCollection 2019.

3.

HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy.

Xu Y, Trumble IM, Warren JA, Clutton G, Abad-Fernandez M, Kirchnerr J, Adimora AA, Deeks SG, Margolis DM, Kuruc JD, Gay CL, Archin NM, Mollan KR, Hudgens M, Goonetilleke N.

Mol Ther Methods Clin Dev. 2019 Aug 14;15:9-17. doi: 10.1016/j.omtm.2019.07.008. eCollection 2019 Dec 13.

4.

How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?

Margolis DM, Deeks SG.

J Infect Dis. 2019 Jul 2;220(Supplement_1):S24-S26. doi: 10.1093/infdis/jiz222.

PMID:
31264691
5.

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.

Garrido C, Tolstrup M, Søgaard OS, Rasmussen TA, Allard B, Soriano-Sarabia N, Archin NM, Margolis DM.

AIDS. 2019 Mar 15;33(4):605-613. doi: 10.1097/QAD.0000000000002112.

PMID:
30830886
6.

Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design.

Ke R, Conway JM, Margolis DM, Perelson AS.

JCI Insight. 2018 Oct 18;3(20). pii: 123052. doi: 10.1172/jci.insight.123052.

7.

Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency.

Bradley T, Ferrari G, Haynes BF, Margolis DM, Browne EP.

Cell Rep. 2018 Oct 2;25(1):107-117.e3. doi: 10.1016/j.celrep.2018.09.020.

8.

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Sung JA, Patel S, Clohosey ML, Roesch L, Tripic T, Kuruc JD, Archin N, Hanley PJ, Cruz CR, Goonetilleke N, Eron JJ, Rooney CM, Gay CL, Bollard CM, Margolis DM.

Mol Ther. 2018 Oct 3;26(10):2496-2506. doi: 10.1016/j.ymthe.2018.08.015. Epub 2018 Sep 21.

9.

Correction to: HIV Persistence on Antiretroviral Therapy and Barriers to a Cure.

Sung JM, Margolis DM.

Adv Exp Med Biol. 2018;1075:E1. doi: 10.1007/978-981-13-0484-2_13.

PMID:
30196367
10.

HIV Persistence on Antiretroviral Therapy and Barriers to a Cure.

Sung JM, Margolis DM.

Adv Exp Med Biol. 2018;1075:165-185. doi: 10.1007/978-981-13-0484-2_7. Review. Erratum in: Adv Exp Med Biol. 2018;1075:E1.

PMID:
30030793
11.

HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.

Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ.

J Clin Invest. 2018 Aug 31;128(9):4074-4085. doi: 10.1172/JCI120549. Epub 2018 Aug 20.

12.

γδ T cells: an immunotherapeutic approach for HIV cure strategies.

Garrido C, Clohosey ML, Whitworth CP, Hudgens M, Margolis DM, Soriano-Sarabia N.

JCI Insight. 2018 Jun 21;3(12). pii: 120121. doi: 10.1172/jci.insight.120121. eCollection 2018 Jun 21.

13.

HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Patel S, Chorvinsky E, Albihani S, Cruz CR, Jones RB, Shpall EJ, Margolis DM, Ambinder RF, Bollard CM.

Mol Ther. 2018 Jun 6;26(6):1435-1446. doi: 10.1016/j.ymthe.2018.04.009. Epub 2018 Apr 12.

14.

Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo.

Garrido C, Abad-Fernandez M, Tuyishime M, Pollara JJ, Ferrari G, Soriano-Sarabia N, Margolis DM.

J Virol. 2018 May 29;92(12). pii: e00235-18. doi: 10.1128/JVI.00235-18. Print 2018 Jun 15.

15.

HIV latency is reversed by ACSS2-driven histone crotonylation.

Jiang G, Nguyen D, Archin NM, Yukl SA, Méndez-Lagares G, Tang Y, Elsheikh MM, Thompson GR 3rd, Hartigan-O'Connor DJ, Margolis DM, Wong JK, Dandekar S.

J Clin Invest. 2018 Mar 1;128(3):1190-1198. doi: 10.1172/JCI98071. Epub 2018 Feb 19.

16.

Countering HIV - Three's the Charm?

Margolis DM, Garcia JV.

N Engl J Med. 2018 Jan 18;378(3):295-297. doi: 10.1056/NEJMcibr1712494. No abstract available.

PMID:
29342376
17.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, Barnard RJ, Blair W, Søgaard OS, Tolstrup M, Østergaard L, Rasmussen TA, Sekaly RP, Archin NM, Margolis DM, Hazuda DJ, Howell BJ.

JCI Insight. 2017 Aug 17;2(16). pii: 92901. doi: 10.1172/jci.insight.92901. eCollection 2017 Aug 17.

18.

Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.

Sung JA, Sholtis K, Kirchherr J, Kuruc JD, Gay CL, Nordstrom JL, Bollard CM, Archin NM, Margolis DM.

EBioMedicine. 2017 Sep;23:52-58. doi: 10.1016/j.ebiom.2017.07.019. Epub 2017 Jul 29.

19.

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD, Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM.

J Clin Invest. 2017 Aug 1;127(8):3126-3135. doi: 10.1172/JCI92684. Epub 2017 Jul 17.

20.

Chromatin Regulation and the Histone Code in HIV Latency
.

Turner AW, Margolis DM.

Yale J Biol Med. 2017 Jun 23;90(2):229-243. eCollection 2017 Jun. Review.

21.

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.

Gay CL, DeBenedette MA, Tcherepanova IY, Gamble A, Lewis WE, Cope AB, Kuruc JD, McGee KS, Kearney MF, Coffin JM, Archin NM, Hicks CB, Eron JJ, Nicolette CA, Margolis DM.

AIDS Res Hum Retroviruses. 2018 Jan;34(1):111-122. doi: 10.1089/aid.2017.0071. Epub 2017 Jun 21.

22.

Towards an HIV Cure: a View of a Developing Field.

Margolis DM.

J Infect Dis. 2017 Mar 15;215(suppl_3):S109-S110. doi: 10.1093/infdis/jiw633. No abstract available.

23.

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.

Margolis DM, Archin NM.

J Infect Dis. 2017 Mar 15;215(suppl_3):S111-S118. doi: 10.1093/infdis/jiw618. Review.

24.

Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations.

Garner SA, Rennie S, Ananworanich J, Dube K, Margolis DM, Sugarman J, Tressler R, Gilbertson A, Dawson L.

J Virus Erad. 2017 Apr 1;3(2):82-84.

25.

Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation.

Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V.

Cell Rep. 2017 Jan 31;18(5):1324-1334. doi: 10.1016/j.celrep.2017.01.022.

26.

HIV antibodies for treatment of HIV infection.

Margolis DM, Koup RA, Ferrari G.

Immunol Rev. 2017 Jan;275(1):313-323. doi: 10.1111/imr.12506. Review.

27.

Detection of human immunodeficiency virus RNAs in living cells using Spinach RNA aptamers.

Burch BD, Garrido C, Margolis DM.

Virus Res. 2017 Jan 15;228:141-146. doi: 10.1016/j.virusres.2016.11.031. Epub 2016 Nov 30.

28.

Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model.

White CH, Moesker B, Beliakova-Bethell N, Martins LJ, Spina CA, Margolis DM, Richman DD, Planelles V, Bosque A, Woelk CH.

PLoS Pathog. 2016 Nov 29;12(11):e1006026. doi: 10.1371/journal.ppat.1006026. eCollection 2016 Nov.

29.

Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection.

Ferrari G, Haynes BF, Koenig S, Nordstrom JL, Margolis DM, Tomaras GD.

Nat Rev Drug Discov. 2016 Dec;15(12):823-834. doi: 10.1038/nrd.2016.173. Epub 2016 Oct 7. Review.

30.

A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?

Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC.

Pathog Immun. 2016 Spring;1(1):154-164.

31.

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function.

Garrido C, Spivak AM, Soriano-Sarabia N, Checkley MA, Barker E, Karn J, Planelles V, Margolis DM.

Front Immunol. 2016 Sep 21;7:356. eCollection 2016.

32.

Corrigendum: The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.

Clutton G, Xu Y, Baldoni PL, Mollan KR, Kirchherr J, Newhard W, Cox K, Kuruc JD, Kashuba A, Barnard R, Archin N, Gay CL, Hudgens MG, Margolis DM, Goonetilleke N.

Sci Rep. 2016 Oct 3;6:34430. doi: 10.1038/srep34430. No abstract available.

33.

Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay.

Lee SK, Zhou S, Baldoni PL, Spielvogel E, Archin NM, Hudgens MG, Margolis DM, Swanstrom R.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):221-228. doi: 10.1097/QAI.0000000000001187.

34.

Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.

Gay CL, Willis SJ, Cope AB, Kuruc JD, McGee KS, Sebastian J, Crooks AM, McKellar MS, Margolis DM, Fiscus SA, Hicks CB, Ferrari G, Eron JJ; Duke-UNC Acute HIV Infection Consortium.

AIDS. 2016 Nov 28;30(18):2815-2822.

35.

Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA.

Margolis DM, Salzwedel K, Chomont N, Psomas C, Routy JP, Poli G, Lafeuillade A.

J Virus Erad. 2016 Jan 1;2(1):57-65.

36.

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.

Clutton G, Xu Y, Baldoni PL, Mollan KR, Kirchherr J, Newhard W, Cox K, Kuruc JD, Kashuba A, Barnard R, Archin N, Gay CL, Hudgens MG, Margolis DM, Goonetilleke N.

Sci Rep. 2016 Aug 2;6:30749. doi: 10.1038/srep30749. Erratum in: Sci Rep. 2016 Oct 03;6:34430.

37.

Latency reversal and viral clearance to cure HIV-1.

Margolis DM, Garcia JV, Hazuda DJ, Haynes BF.

Science. 2016 Jul 22;353(6297):aaf6517. doi: 10.1126/science.aaf6517. Review.

38.

Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril JG, McKellar M, Margolis DM, Trottier B, Wood K, Nicolette C.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8. doi: 10.1097/QAI.0000000000000926.

39.

HIV reservoirs: what, where and how to target them.

Churchill MJ, Deeks SG, Margolis DM, Siliciano RF, Swanstrom R.

Nat Rev Microbiol. 2016 Jan;14(1):55-60. doi: 10.1038/nrmicro.2015.5. Epub 2015 Nov 30. Review.

PMID:
26616417
40.

Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection.

Soriano-Sarabia N, Archin NM, Bateson R, Dahl NP, Crooks AM, Kuruc JD, Garrido C, Margolis DM.

PLoS Pathog. 2015 Oct 16;11(10):e1005201. doi: 10.1371/journal.ppat.1005201. eCollection 2015 Oct.

41.

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

Sung JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CY, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, Yang Y, Parks R, Archin N, Allard B, Kirchherr J, Kuruc JD, Gay CL, Cohen MS, Ochsenbauer C, Soderberg K, Liao HX, Montefiori D, Moore P, Johnson S, Koenig S, Haynes BF, Nordstrom JL, Margolis DM, Ferrari G.

J Clin Invest. 2015 Nov 2;125(11):4077-90. doi: 10.1172/JCI82314. Epub 2015 Sep 28.

42.

Characterizing the Switching Thresholds of Magnetophoretic Transistors.

Abedini-Nassab R, Joh DY, Van Heest MA, Yi JS, Baker C, Taherifard Z, Margolis DM, Garcia JV, Chilkoti A, Murdoch DM, Yellen BB.

Adv Mater. 2015 Oct 28;27(40):6176-80. doi: 10.1002/adma.201502352. Epub 2015 Sep 9.

43.

Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency.

White CH, Johnston HE, Moesker B, Manousopoulou A, Margolis DM, Richman DD, Spina CA, Garbis SD, Woelk CH, Beliakova-Bethell N.

Antiviral Res. 2015 Nov;123:78-85. doi: 10.1016/j.antiviral.2015.09.002. Epub 2015 Sep 4.

44.

Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.

Reardon B, Beliakova-Bethell N, Spina CA, Singhania A, Margolis DM, Richman DR, Woelk CH.

AIDS. 2015 Nov;29(17):2235-44. doi: 10.1097/QAD.0000000000000839.

45.

Gold nanoparticles to improve HIV drug delivery.

Garrido C, Simpson CA, Dahl NP, Bresee J, Whitehead DC, Lindsey EA, Harris TL, Smith CA, Carter CJ, Feldheim DL, Melander C, Margolis DM.

Future Med Chem. 2015;7(9):1097-107. doi: 10.4155/fmc.15.57.

46.

H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.

Tripathy MK, McManamy ME, Burch BD, Archin NM, Margolis DM.

J Virol. 2015 Aug;89(16):8392-405. doi: 10.1128/JVI.00572-15. Epub 2015 Jun 3.

47.

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL, Eron JJ, Margolis DM, Bosch RJ, Archin NM.

J Infect Dis. 2015 Nov 1;212(9):1361-5. doi: 10.1093/infdis/jiv218. Epub 2015 Apr 15.

48.

HIV eradication symposium: will the brain be left behind?

Brew BJ, Robertson K, Wright EJ, Churchill M, Crowe SM, Cysique LA, Deeks S, Garcia JV, Gelman B, Gray LR, Johnson T, Joseph J, Margolis DM, Mankowski JL, Spencer B.

J Neurovirol. 2015 Jun;21(3):322-34. doi: 10.1007/s13365-015-0322-6. Epub 2015 Mar 7.

49.

Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.

Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, Margolis DM.

J Infect Dis. 2015 Jul 15;212(2):258-63. doi: 10.1093/infdis/jiv022. Epub 2015 Jan 13.

50.

Eradicating HIV-1 infection: seeking to clear a persistent pathogen.

Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM.

Nat Rev Microbiol. 2014 Nov;12(11):750-64. doi: 10.1038/nrmicro3352. Review.

Supplemental Content

Loading ...
Support Center